Exact Sciences Corporation (EXAS) Insider Graham Peter Lidgard Sells 45,775 Shares of Stock

Exact Sciences Corporation (NASDAQ:EXAS) insider Graham Peter Lidgard sold 45,775 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $53.60, for a total transaction of $2,453,540.00. Following the completion of the sale, the insider now directly owns 272,819 shares in the company, valued at $14,623,098.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Graham Peter Lidgard also recently made the following trade(s):

  • On Monday, October 2nd, Graham Peter Lidgard sold 81,025 shares of Exact Sciences Corporation stock. The stock was sold at an average price of $47.16, for a total transaction of $3,821,139.00.
  • On Tuesday, September 5th, Graham Peter Lidgard sold 75,683 shares of Exact Sciences Corporation stock. The stock was sold at an average price of $40.81, for a total transaction of $3,088,623.23.
  • On Friday, September 1st, Graham Peter Lidgard sold 45,775 shares of Exact Sciences Corporation stock. The shares were sold at an average price of $41.49, for a total transaction of $1,899,204.75.

Shares of Exact Sciences Corporation (NASDAQ:EXAS) traded up $3.70 during mid-day trading on Friday, reaching $56.71. The company had a trading volume of 1,500,141 shares, compared to its average volume of 1,840,000. Exact Sciences Corporation has a 12 month low of $13.05 and a 12 month high of $57.95. The company has a quick ratio of 16.42, a current ratio of 10.34 and a debt-to-equity ratio of 0.01.

Exact Sciences Corporation (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The company had revenue of $72.60 million during the quarter, compared to analyst estimates of $65.03 million. During the same quarter last year, the firm posted ($0.36) earnings per share. The firm’s revenue was up 158.4% on a year-over-year basis. sell-side analysts anticipate that Exact Sciences Corporation will post -1.14 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/11/04/exact-sciences-corporation-exas-insider-graham-peter-lidgard-sells-45775-shares-of-stock.html.

A number of hedge funds have recently made changes to their positions in EXAS. Fortaleza Asset Management Inc. purchased a new stake in Exact Sciences Corporation in the second quarter worth $106,000. Krilogy Financial LLC lifted its stake in Exact Sciences Corporation by 1,460.0% in the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after acquiring an additional 3,650 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in Exact Sciences Corporation by 17.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock worth $144,000 after acquiring an additional 600 shares during the period. Financial Architects Inc lifted its stake in Exact Sciences Corporation by 90.0% in the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock worth $152,000 after acquiring an additional 2,035 shares during the period. Finally, Johnson Financial Group Inc. lifted its stake in Exact Sciences Corporation by 25.9% in the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock worth $172,000 after acquiring an additional 1,000 shares during the period. 85.12% of the stock is owned by institutional investors.

A number of research analysts have commented on the stock. Zacks Investment Research cut shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research report on Thursday. BTIG Research cut shares of Exact Sciences Corporation from a “buy” rating to a “neutral” rating in a research report on Wednesday. Bank of America Corporation increased their price target on shares of Exact Sciences Corporation from $56.00 to $58.00 and gave the company a “buy” rating in a research report on Tuesday. Canaccord Genuity upgraded shares of Exact Sciences Corporation to a “buy” rating and set a $60.00 price target on the stock in a research report on Tuesday. Finally, Robert W. Baird increased their price target on shares of Exact Sciences Corporation from $49.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Exact Sciences Corporation has a consensus rating of “Buy” and an average target price of $49.71.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

What are top analysts saying about Exact Sciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exact Sciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit